Professor Mary Collins
Mary Collins was Head of the Division of Advanced Therapies from 2014-2016. At NIBSC she led a research team of approximately 5 PhD students and post-doctoral fellows aiming to engineer viruses for experimental and clinical gene delivery. The group produced the first stable packaging cells for lentiviral vectors, investigated the use of lentiviral vectors as vaccines and determined how Kaposi’s sarcoma-associated herpes virus activates the NFκB pathway.
Prior to her arrival at NIBSC, Mary was Dean of the Faculty of Life Sciences at UCL. In 2016 she took up the position of Dean of Research at the Okinawa Institute of Science and Technology in Japan.